COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Call for Applications – Clinical Assay Development Program

The NCI Clinical Assay Development Program (CADP) is requesting project applications from investigators seeking clinical assay validation resources.  These resources are designed to assist with the development of assays that may predict therapy response or prognostic behavior of a diagnosed cancer, primarily for use in clinical trials. Approved projects for the NCI CADP will be provided access to the Institute’s assay development and validation resources, including project management support.

When applying to the CADP, it is important that investigators define the intended clinical use for the assay for which support is requested.  Assays submitted for CADP development services should have been tested on human tissue. As part of the application, investigators are required to provide basic assay protocol(s). Proposals will be reviewed for scientific merit, feasibility and clinical importance.

Application deadline: October 15, 2012.

To learn more about CADP or to submit an application, go to http://cadp.cancer.gov.

Please note this call for application is not a solicitation for biomarker discovery and is not a grants program.